<DOC>
	<DOCNO>NCT00564772</DOCNO>
	<brief_summary>This open-label , 3-period , fix sequence study young , healthy , male female subject pharmacokinetic interaction raltegravir Kaletra .</brief_summary>
	<brief_title>Raltegravir Kaletra Pharmacokinetics</brief_title>
	<detailed_description>This open-label , 3-period , fix sequence study young , healthy , male female subject . The initial cohort , study simultaneously , 15 subject intention collect complete data 12 subject . Replacements subsequently enrol necessary . Subjects reimburse . The period - Period 1 : Raltegravir ( RAL ) 400 mg q12h 4 day ( 7 dos RAL ) . - Period 2 : Kaletra 200 mg 2 pill bid 10 day ( 19 dos Kaletra ) . - Period 3 : regimen 4 day ( 7 dos drug ) . All morning dose observed Prism Research , Inc. Evening dos distribute morning . 12 hour PK study do last day period . Specimens obtain 0 , 0.5 , 1 , 1.5 , 2 , 3 , 4 , 5 , 6 , 8 , 10 , 12 hour morning dose last dosing day period .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Healthy , male female , age 1855 . AntiHIV , antiHCV , HBsAg negative . Normal history physical screening . Normal complete blood count , creatinine ALT screening . Negative urine pregnancy test screening . BMI 1830 . Donated blood month Day 1 . Participated another research study month Day 1 . Tobacco use 3 month Day 1 , unwillingness avoid tobacco use study . Use illegal drug year Day 1 , positive drug screen illegal drug screening . Unwillingness restrict coffee use 6 few cup coffee study . Unwillingness part fertile female subject abstinent use two effective birth control method , one barrier method , vaginal intercourse . Unwillingness avoid use prescribed medication study Allergy RAL , lopinavir ritonavir .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>raltegravir</keyword>
	<keyword>lopinavir</keyword>
	<keyword>ritonavir</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>